Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2009

Morphotek Taps Synageva in Cancer and Infectious Disease Deal

  • Morphotek entered a research agreement with Synageva BioPharma to express and develop therapeutic mAbs for the treatment of various cancers and infectious diseases. The Synageva Expression Platform (SEP™), which is an integrated technology for protein production, processing, and purification, will be used.

    Morphotek’s pipeline includes MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II, and MORAb-004 in Phase I trials in solid tumors. “We are always exploring new ways that may enhance the manufacturing process for our antibody products,” states Philip M. Sass, Ph.D., evp and COO, Morphotek.

    Morphotek develops optimized antibodies for therapeutic applications and high-titer manufacturing cell lines using Morphodoma®. The antibodies within the company's pipeline are targeted against antigens licensed from its collaborative partners.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »